EVOQ secures strategic investment from global business leader & philanthropist Tony Robbins to advance next-generation antimicrobial metamaterial technology

SALT LAKE CITY, Jan. 30, 2025 — EVOQ, a nanoscience company that engineers novel metamaterial for the life, material, and textile science industries, today announced a strategic investment from Tony Robbins, the renowned business and life strategist, #1 New York Times bestselling author, entrepreneur, and philanthropist. The partnership will support the continued development of EVOQ’s groundbreaking antimicrobial metamaterial platform.

“I’ve always looked to support innovative advancements in health technology, and EVOQ’s approach to fighting antibiotic-resistant bacteria addresses an urgent global challenge,” said Mr. Robbins. “This game-changing technology has the potential to save millions of lives and transform how we approach infection prevention and treatment.”

The investment comes at a crucial time. The World Health Organization (WHO) has identified antimicrobial resistance as one of the top 10 global public health threats. EVOQ’s antimicrobial metamaterial platform has demonstrated effectiveness against the WHO’s top six antibiotic-resistant bacterial strains without triggering resistance, offering a promising solution to this growing healthcare challenge.

Mr. Robbins will also join the company’s advisory board. “Having Mr. Robbins join us as both an investor and strategic partner marks a significant milestone in EVOQ’s journey,” said Shaun Rothwell, CEO of EVOQ. “Mr. Robbins’ global reach, business acumen, and passion for improving lives align perfectly with our mission. His support will be instrumental in advancing the development of our pioneering technology.”

The strategic investment will support EVOQ’s development initiatives across three core industries:

EVOQ Bio has developed an inhaled therapeutic using the metamaterial EVQ-218 for the treatment of pulmonary bacterial infections in patients with cystic fibrosis, in partnership with the Cystic Fibrosis Foundation. The company recently completed a successful Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration and is confidently advancing toward Phase I clinical trials.

EVOQ MedTech integrates EVQ-218’s antimicrobial capabilities into medical devices to defend against a broad spectrum of contaminants like bacteria and fungi. The team is collaborating with leading catheter manufacturers with the aim of curbing healthcare-associated infections (HAIs), impacting more than 1 million hospital patients annually.

FUZE Technologies serves the textile, hospitality, fitness, and workspace industries. Its antimicrobial technology approved by the Environmental Protection Agency is free of chemicals, toxicity, and environmental waste. FUZE is working with some of the world’s most notable brands, including Nike, Adidas, the New England Patriots, Marriott, and Hilton.

Beyond its current applications, EVOQ’s technology platform has the potential to impact multiple industries. In the energy sector: protecting critical infrastructure against corrosion while boosting battery performance and longevity. In agriculture: combating plant pathogens and enhancing food safety throughout the supply chain.

Tony Robbins is an eight-time #1 New York Times bestselling author, entrepreneur, peak performance coach, and life and business strategist. A recognized authority on the psychology of leadership, negotiations, and organizational turnaround, he has served as an advisor to leaders around the world for more than 40 years. He is also a philanthropist whose influence extends globally, positively impacting over 50 million individuals across 100 countries through his audio programs, educational videos, and live seminars.

EVOQ is a metamaterial platform technology company that engineers novel metamaterial for the life, materials, and textile science industries. The company’s multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm metamaterial with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com.

For EVOQ:

EVOQ Comms

comms@evoqmm.com

For Tony Robbins: